Fayanju, Oluwadamilola M. http://orcid.org/0000-0002-0876-975X
Ren, Yi
Greenup, Rachel A.
Plichta, Jennifer K.
Rosenberger, Laura H.
Force, Jeremy
Suneja, Gita
Devi, Gayathri R.
King, Tari A.
Nakhlis, Faina
Hyslop, Terry
Hwang, E. Shelley
Funding for this research was provided by:
National Center for Advancing Translational Sciences (1KL2TR002554)
National Cancer Institute (1K08CA241390)
National Institutes of Health (K08CA228631, P30AI064518, P30CA014236)
Office of Research on Women's Health (K12HD043446)
U.S. Department of Defense (W81XWH-17-1-0297)
IBC Network Foundation
Article History
Received: 29 September 2019
Accepted: 9 January 2020
First Online: 20 January 2020
Compliance with ethical standards
:
: Dr. Force is a consultant for Genomic Health, Nanostring, and Pfizer, Dr. King is a consultant for Genomic Health, Dr. Hyslop is a consultant for AbbVie, and Dr. Fayanju, Mr. Ren, Dr. Greenup, Dr. Plichta, Dr. Rosenberger, Dr. Suneja, Dr. Devi, Dr. Nakhlis, and Dr. Hwang have no conflicts of interest to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with human participants or animals performed by any of the authors as de-identified data were used and the study was granted exempt status by our institutional review board.